By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Swiss Investors Going Direct, Avoiding Funds
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Swiss Investors Going Direct, Avoiding Funds
Business

Swiss Investors Going Direct, Avoiding Funds

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

“The Biotech VC Fund industry has been put to a standstill in Europe.

“The Biotech VC Fund industry has been put to a standstill in Europe. There have been no new funds of significant scope raised in Europe the past three years, except from the fiscally-denominated Retail French FCPI and F-ISF” according to Swiss investor Hervé de Kergrohen, a medical doctor who has been active as a financer for emerging biotech and medical technology companies in the region since 2001.  “Switzerland is a special place. There is a lot of money from around the world here, including Russia and the Middle East, that is looking for investments. In my experience there is still a great deal of money sitting on the sidelines looking for returns.”

But Kergrohen notes there is a major move away from funds by family offices to a desire for direct control of investments themselves. He also notes that the investors are looking for investments that fit their special needs. They are not, indeed, “mandated” to invest in any specific technologies and their horizons are much shorter than VC funds. They are just looking for bargains with quick exits in this depressed market for venture investing. In their asset allocation, there still is a place for private equity and innovation, but not through funds. As they do not possess internal expertise on Biotech or Medtech investing, they welcome the quality of the deal flow that GlenBrook selects for them. They also mandate GlenBrook to follow their investments after the initial transaction in order to monitor growth and ensure a timely exit.

Hervé de Kergrohen, who recently formed  GlenBrook Ventures, an investment company that picks out the diamonds from around the world, will be joining the advisory board of the OneMedForum New York.

More Read

The Anti-Aging Empire: Infographic
How To Become An Emergency Preparedness Administrator
Leave No Patient on the Battlefield
Hospital Promotional Partners Leverage Clever Ideas for Greater Impact
How Is Marketing a Healthcare Practice Different?

“The idea of this Trans-Atlantic conference is very unique and makes good sense. Increasingly in a global market, connectivity between Europe and the US is important,” according to Kergrohen.  “Communications is making the world smaller and for many investors geography is less important.”

Hervé de Kergrohen’s experience is considerable.  He founded the BioData a Geneva Conference in 2001 that has attracted as many as 300-400 attendees to this annual event.  “Herve brings an exceptional list of European investors we hope will join us in New York ”  said Jon Garfield, a co-chair of the conference advisory board who recruited Herve, adding “we are looking to recruit well regarded and well known investors from Europe, although Ultra-High-Net-Worth-Individuals usually do not appear themselves and are sometimes represented by their personal advisors.”  Kergrohen joins an already distinguished group of Europeans that have signed on. Other notables who have recently joined include Klaas de Boer from the Entrepreneurs Fund in England, Marco Elser from Advicorp in Rome and Financier Pietro Strada also from England. See full list of advisors.

Glenbrook Ventures has secured mandates, either from large private equity investors, or from selected biopharma and medical technology companies. GlenBrook raises 2 to 15 million dollars per deal.  It intends to continue to conclude 3 to 4 deals per year, in early- as well as late-stage projects. Advisors to GlenBrook are senior executives from the Health Care Industry able to commit of their own funds and offer their network to attractive projects. –Brett Johnson

 

TAGGED:health care business
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

Medical Practice Marketing, Search Marketing, Physician Marketing
BusinesseHealth

Search Marketing Tips for the Small Medical Practice

August 2, 2014
physician burnout
BusinessHospital AdministrationWellness

Physician Burnout and the Enlightened CFO

April 13, 2013
Business

The 3 Essentials To Keep In Mind When Opening An Independent Pharmacy

November 22, 2021

FDA Warning Letter Highlights Disconnect Between Regulator and Biotech Industry

December 5, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?